(Q34119634)

31 July 2017

1 reference

title

Pemetrexed disodium, a novel antifolate with multiple targets (English)

1 reference

31 July 2017

N J Curtin

1

1 reference

31 July 2017

A N Hughes

series ordinal

2

1 reference

31 July 2017

publication date

1 May 2001

1 reference

Lancet Oncology Commission

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

298-306

1 reference

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Folate-based thymidylate synthase inhibitors as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-(( 2-amino-4-hydroxy-6-quinazolinyl)methyl)prop-2-ynylamino) benzoyl)-L-glutamic acid (CB3717), on human lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Glutamyl hydrolase and the multitargeted antifolate LY231514.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Thymidine concentrations in serum and urine of different animal species and man

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Modulation of anti-metabolite effects. Effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2800%2900325-9

7 January 2021

10.1016/S1470-2045(00)00325-9

Identifiers

DOI

1 reference

31 July 2017

1 reference